

Cancer Immunology Immunotherapy

Founding Editor
G. Mathé

Other Biological Response Modifications

Volume 27 1988

Editors in Chief

R. W. Baldwin E. Mihich

Editorial Board

R. Arnon Rehovot
R. Bast Durham, NC
S. Ben-Efraim Tel Aviv
J. Bennett Albany, NY
N. Bloksma Utrecht
T. Boon Brussels
E. C. Borden Madison, WI
V. S. Byers Berkeley, CA
T. Carey Ann Arbor, MI
M. Cheever Seattle, WA
M. Colnaghi Milan
W. Den Otter Utrecht
S. Dray Chicago, IL
S. Eccles Sutton, Surrey

I. Fidler Houston, TX
E. Grimm Houston, TX
K. Hellström Seattle, WA
J. Kieler Copenhagen
H. Kirchner Heidelberg
H. Kobayashi Sapporo
M. Mastrangelo Philadelphia, PA
J. McVie Amsterdam
M. Micksche Vienna
M. Mitchell Los Angeles, CA
R. J. North Saranac Lake, NY
G. Parmiani Milan
H. M. Pinedo Amsterdam
T. J. Priestman Birmingham

R. Rees Sheffield
P. Rümke Amsterdam
D. Scott Rochester, NY
K. Sikora London
Z. Stepwski Philadelphia, PA
G. Stevenson Southampton
J. Talmadge King of Prussia, PA
E. Tsubura Osaka
A. Uchida Kyoto
F. Vánky Stockholm
E. Vitetta Dallas, TX
B. Vose Cheshire
Y. Yamamura Osaka



Springer International

Cancer Immunology Immunotherapy

Other Biological Response Modifications

This journal was founded in 1976. Founding editor: G. Mathé

Editors: R. W. Baldwin, E. Mihich

Published by Springer International

Copyright

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for photocopies in the USA: Photocopies may be made for personal or inhouse use beyond the limitations stipulated under Section 107 or 108 of U.S. Copyright Law, provided a fee is paid. This fee is US \$ 0.20 per page, or a minimum of US \$ 1.00 if an article contains fewer than five pages. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0340-7004, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

Printed in Germany by E. Kieser GmbH Graphischer Betrieb, D-8902 Neusäß bei Augsburg

© Springer-Verlag Berlin Heidelberg 1988

Contents of volume 27

No. 1 (pp 1-96) published July 18, 1988
 No. 2 (pp 97-190) published August 26, 1988
 No. 3 (pp 191-282) published October 3, 1988

- Abo T → Fujii M, et al. 97
 Ackermann MF → Germolec DR, et al. 121
 Advani SH → Somasundaram R, et al. 177
 Advani SH → Somasundaram R, et al. 183
 Agüero B → Wong JH, et al. 142
 Ahmad A: Immunotoxins: what is there in a scientific term? 95
 Allavena P → Di Bello M, et al. 63
 Allavena P, Lo Presti P, Di Bello M, Lucchini V, Lissoni A, Zanetta G, Mangioni C, Mantovani A: Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells 69
 Anderson PM, Bach FH, Ochoa AC: Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma 82
 Bach FH → Anderson PM, et al. 82
 Baldwin RW → Byers VS, et al. 77
 Baldwin RW → Pimm MV, et al. 267
 Ben-Efraim S → Elliott GR, et al. 133
 Benrezzak O → Bissonnette E, et al. 272
 Berek JS → Nio Y, et al. 246
 Biberfeld P → Shetye J, et al. 154
 Bissonnette E, Benrezzak O, Madarnas P, Brailovsky C, Nigam VN: Mitogenic, immunoadjuvancy, and genetic studies on fatty acyl maltose 272
 Blasi E, Varesio L, Wiltrout RH: Tumor formation by a murine macrophage cell line immortalized in vitro by *v-ras* and *v-myc* oncogenes 109
 Bonavida B → Nio Y, et al. 246
 Bonmassar E → D'Atri S, et al. 163
 Bonta IL → Elliott GR, et al. 133
 Böök K → Vánky F, et al. 213
 Boon T → Weynants P, et al. 228
 Bouwens L, Jacobs R, Remels L, Wisse E: Natural cytotoxicity of rat hepatic natural killer cells and macrophages against a syngeneic colon adenocarcinoma 137
 Brailovsky C → Bissonnette E, et al. 272
 Brusa P → Cattell L, et al. 233
 Bühring H-J → Pawelec G, et al. 89
 Byers VS, Levin AS, Ozonow DM, Baldwin RW: Association between clinical symptoms and lymphocyte abnormalities in a population with chronic domestic exposure to industrial solvent contaminated domestic water supply and a high incidence of leukaemia 77
 Cattell L, Delprino L, Brusa P, Dosio F, Comoglio PM, Prat M: Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines 233
 Chiari S → Di Bello M, et al. 63
 Christensson B → Shetye J, et al. 154
 Colleoni R → Di Bello M, et al. 63
 Colombo N → Di Bello M, et al. 63
 Comoglio PM → Cattell L, et al. 233
 Coullie PG → Weynants P, et al. 228
 Crump III WL → Grimm EA, et al. 53
 Czerwenka K → Tichatschek E, et al. 278
 Czupryna A → Uracz W, et al. 171
 Delprino L → Cattell L, et al. 233
 De Vecchis L → D'Atri S, et al. 163
 Di Bello M, Lucchini V, Chiari S, Colleoni R, Colombo N, Mantovani A, Allavena P: DR antigen expression on ovarian carcinoma cells does not correlate with their capacity to elicit an autologous proliferative response 63
 Di Bello M → Allavena P, et al. 69
 Dittrich K → Germolec DR, et al. 121
 Dosio F → Cattell L, et al. 233
 Dray S → Wise JA, et al. 191
 Durett A → Grimm EA, et al. 53
 Eble JN → Johnson DA, et al. 241
 Ehninger G → Pawelec G, et al. 89
 Ehrke MJ, Ho RLX, Hori K: Species-specific TNF induction of thymocyte proliferation 103
 Eibl MM → Tichatschek E, et al. 278
 Elliot GR, Tak C, Pellens C, Ben-Efraim S, Bonta IL: Indomethacin stimulation of macrophage cytolysis against MOPC-315 tumor cells is inhibited by both prostaglandin E_2 and nordihydroguaiaretic acid, a lipoxygenase inhibitor 133
 Eura M, Maehara T, Ikawa T, Ishikawa T: Suppressor cells in the effector phase of autologous cytotoxic reactions in cancer patients 147
 Faulkner G → Singh M, et al. 17
 Fidler IJ → Morikawa K, et al. 1
 Fidler IJ → Ichinose Y, et al. 7
 Frödin J-E → Shetye J, et al. 154
 Fuggetta MP → D'Atri S, et al. 163
 Fujii M, Abo T, Kumagai K: Cytokines produced by blood mononuclear cells stimulated with the streptococcal preparation OK-432: effect on production by supplementing the medium with xenogeneic serum 97
 Fujiwara H → Sakamoto K, et al. 261
 Fukuda Y, Imai K, Miura K, Matsui M, Nakanishi T, Nakazato H, Masukawa J, Higashide T, Hinoda Y, Noguchi T, Yachi A: A monoclonal antibody to the carbohydrate chain on human hepatocellular carcinoma-associated antigen which suppressed tumor growth in nude mice 26
 Furukawa T → Miyamoto K, et al. 59
 Gallati H → Voth R, et al. 128
 Gangal SG → Somasundaram R, et al. 177
 Gangal SG → Somasundaram R, et al. 183
 Germolec DR, Maronpot RR, Ackermann MF, Vore SJ, Dittrich K, Rosenthal GJ, Luster MI: Lack of a relationship between immune function and chemically induced hepatocarcinogenesis in B6C3F₁ mice 121
 Ghose TI → Singh M, et al. 17
 Giganti G → D'Atri S, et al. 163
 Golub SH → Shau H, et al. 255
 Grant C → Shetye J, et al. 154
 Gray JD → Shau H, et al. 255
 Grimm EA, Crump III WL, Durett A, Hester JP, Lagoo-Deenadalan S, Owen-Schaub LB: TGF- β inhibits the in vitro induction of lymphokine-activated killing activity 53
 Gupta RK → Wong JH, et al. 142
 Hamaoka T → Sakamoto K, et al. 261
 Hammersley-Straw DRH → McGarry RC, et al. 47
 Hansson Y, Vargas-Cortes M, Paulie S, Perlmann P: MHC nonrestricted cytotoxic T cell clones with selective specificity from patients with transitional cell carcinoma (TCC) of the urinary bladder 205
 Hasumi K → Shimizu Y, et al. 223
 Hess G → Voth R, et al. 128
 Hester JP → Grimm EA, et al. 53
 Higashide T → Fukuda Y, et al. 26

- Hinoda Y → Fukuda Y, et al. 26
 Hisatsugu T → Katano M, et al. 198
 Ho RLX → Ehrke MJ, et al. 103
 Hori K → Ehrke MJ, et al. 103
- Ichinoe Y, Tsao JY, Fidler IJ: Destruction of tumor cells by monokines released from activated human blood monocytes: evidence for parallel and additive effects of IL-1 and TNF 7
 Ikawa T → Eura M, et al. 147
 Imai K → Fukuda Y, et al. 26
 Imai H, Matsuura H, Kudo M, Nakazawa S: Induction of lymphokine-activated killer cells from rat thymocytes using recombinant human interleukin-2 13
 Inamura N → Sone S, et al. 33
 Ishikawa T → Eura M, et al. 147
 Ivert T → Vánky F, et al. 213
- Jacobs R → Bouwens L, et al. 137
 Jacobsson B → Shetye J, et al. 154
 Jochum C → Voth R, et al. 128
 Johnson DA, Zimmermann JL, Laguzza BC, Eble JN: In vivo antitumor activity demonstrated with squamous carcinoma reactive monoclonal antibody-Vinca immunoconjugates 241
- Kaplan AM → Nagarkatti M, et al. 38
 Katagiri T → Sakamoto K, et al. 261
 Katano M, Yamamoto H, Mizoguchi T, Hisatsugu T: Induction of tumor growth inhibitory factor (TGIF) in human mononuclear cells by OK-432, a streptococcal preparation 198
 Kishi N → Miyamoto K, et al. 59
 Kiyotaki C → Sakamoto K, et al. 261
 Klein E → Vánky F, et al. 213
 Koshiura R → Miyamoto K, et al. 59
 Kubista E → Tichatschek E, et al. 278
 Kudo M → Imai H, et al. 13
 Kumagai K → Fujii M, et al. 97
- Lagoo-Deenadlayan S → Grimm EA, et al. 53
 Laguzza BC → Johnson DA, et al. 241
 Larsson B → Vánky F, et al. 213
 Laubenstein HP → Voth R, et al. 128
 Levin AS → Byers VS, et al. 77
 Lissoni A → Allavena P, et al. 69
 Lo Presti P → Allavena P, et al. 69
 Lucchini V → Di Bello M, et al. 63
 Lucchini V → Allavena P, et al. 69
 Luster MI → Germolec DR, et al. 121
- Madarnas P → Bissonnette E, et al. 272
 Maehara T → Eura M, et al. 147
 Mangioni C → Allavena P, et al. 69
 Mantovani A → Di Bello M, et al. 63
 Mantovani A → Allavena P, et al. 69
 Maronpot RR → Germolec DR, et al. 121
 Masubuchi K → Shimizu Y, et al. 223
 Masukawa J → Fukuda Y, et al. 26
 Matsui M → Fukuda Y, et al. 26
 Matsuura H → Imai H 13
 McGarry RC, Pinto A, Hammersley-Straw DRH, Trevenen CL: Expression of markers shared between human natural killer cells and neuroblastoma lines 47
 Mellstedt H → Shetye J, et al. 154
 Meyer zum Büschenfelde KH → Voth R, et al. 128
 Mezei M → Singh M, et al. 17
 Miura K → Fukuda Y, et al. 26
 Miyamoto K, Kishi N, Murayama T, Furukawa T, Koshiura R: Induction of cytotoxicity of peritoneal exudate cells by agrimoniin, a novel immunomodulatory tannin of *Agrimonia pilosa* Ledeb 59
 Mizoguchi T → Katano M, et al. 198
 Mokyr MB → Wise JA, et al. 191
- Morikawa K, Nayar R, Fidler IJ: In vitro activation of tumoricidal properties in mouse macrophages using the chemotactic peptide *N*-formyl-methionyl-leucyl-phenylalanine (FMLP) incorporated in liposomes 1
 Morton DL → Wong JH, et al. 142
 Müller WEG → Voth R, et al. 128
 Müller C → Tichatschek E, et al. 278
 Murayama T → Miyamoto K, et al. 59
- Nagarkatti M, Nagarkatti PS, Kaplan AM: Differential effects of BCNU on T cell, macrophage, natural killer and lymphokine-activated killer cell activities in mice bearing a syngeneic tumor 38
 Nagarkatti PS → Nagarkatti P, et al. 38
 Nakajima H → Sakamoto K, et al. 261
 Nakanishi T → Fukuda Y, et al. 26
 Nakazato H → Fukuda Y, et al. 26
 Nakazawa S → Imai H, et al. 13
 Nayar R → Morikawa K, et al. 1
 Nigam VN → Bissonnette E, et al. 272
 Nii A → Sone S, et al. 33
 Nio Y, Zigelboim J, Berek JS, Bonavida B: Sensitivity of fresh and cultured ovarian tumor cells to tumor necrosis factor, interferon-alpha 2, and OK-432 246
 Noguchi T → Fukuda Y, et al. 26
 Nolibe D, Thang MN: Stimulation of natural killer cytotoxicity by long-term treatment with double-stranded polynucleotides without induction of hyporesponsiveness 114
 Nunziata C → D'Atri S, et al. 163
- Ochoa AC → Anderson PM, et al. 82
 Ogumuyiwa Y → Pimm MV, et al. 267
 Ogura T → Sone S, et al. 33
 Okubo A → Sone S, et al. 33
 Okudaira Y → Shimizu Y, et al. 223
 Owen-Schaub LB → Grimm EA, et al. 53
 Ozonow DM → Byers VS, et al. 77
- Pastore S → D'Atri S, et al. 163
 Paul MA → Pimm MV, et al. 267
 Paulie G → Hansson Y, et al. 205
 Pawelec G, Schmidt H, Schneider E, Bühring H-J, Ehninger G: Cellular immunological defects of chronic myelogenous leukaemias: partial dependence on busulphan therapy 89
 Pellens C → Elliott GR, et al. 133
 Perlmann P → Hansson Y, et al. 205
 Péterffy A → Vánky F, et al. 213
 Pimm MV, Paul MA, Ogumuyiwa Y, Baldwin RW: Biodistribution and tumour localisation of a daunomycin-monoclonal antibody conjugate in nude mice with human tumour xenografts 267
 Pinto A → McGarry RC, et al. 47
 Pituch-Noworolska A → Uracz W, et al. 171
 Popiela T → Uracz W, et al. 171
 Pracht I → Voth R, et al. 128
 Prat M → Cattel L, et al. 233
- Rao SGA → Somasundaram R, et al. 177
 Remels L → Bouwens L, et al. 137
 Roselli M → D'Atri S, et al. 163
 Rosenthal GJ → Germolec DR, et al. 121
 Rossol S → Voth R, et al. 128
- Sakamoto K, Nakajima H, Shimizu J, Katagiri T, Kiyotaki C, Fujiwara H, Hamaoka T: The mode of recognition of tumor antigens by noncytolytic-type antitumor T cells: Role of antigenpresenting cells and their surface class I and class II H-2 molecules 261
 Schmidt H → Pawelec G, et al. 89
 Schneider E → Pawelec G, et al. 89
 Schröder HC → Voth R, et al. 128
 Sevela P → Tichatschek E, et al. 278

- Shau H, Gray JD, Golub SH: Studies on cytotoxicity generated in human mixed lymphocyte culture. IV. Interleukin 2 alone or from mixed lymphocyte culture yields natural killer-like cytotoxic cells distinct from allospecific cytotoxic T lymphocytes 255
- Shetye J, Frödin J-E, Christensson B, Grant C, Jacobsson B, Sundelius S, Sylven M, Biberfeld P, Mellstedt H: Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A) 154
- Shimizu Y, Hasumi K, Masubuchi K, Okudaira Y: Immunotherapy of tumor-bearing mice virus help 223
- Shimizu J → Sakamoto K, et al. 261
- Singh M, Faulkner G, Ghose TI, Mezei M: Antibody directed targeting of methotrexate-containing small unilamellar vesicles 17
- Sjöwall K → Vánky F, et al. 213
- Somasundaram R, Rao SGA, Advani SH, Gangal SG: In vitro generation of effector cells cytotoxic to autologous targets from chronic myeloid leukemia patients in remission 177
- Somasundaram R, Advani SH, Gangal SG: Propagation of cytotoxic effectors from chronic myeloid leukemia patients and cloning of cytotoxic T cells 183
- Sone S, Okubo A, Inamura N, Nii A, Ogura T: Synergism of synthetic acyltripeptide and its analogs with recombinant interferon γ for activation of antitumor properties of human blood monocytes 33
- Spona J → Tichatschek E, et al. 278
- Stachura J → Uracz W, et al. 171
- Stuber G → Vánky F, et al. 213
- Sundelius S → Shetye J, et al. 154
- Sylven M → Shetye J, et al. 154
- Symann M → Weynants P, et al. 228
- Tak C → Elliott GR, et al. 133
- Tentori L → D'Atri S, et al. 163
- Thang MN → Nolibe D 114
- Tichatschek E, Zielinski CC, Müller C, Sevela P, Kubista E, Czerwenka K, Spona J, Wolf H, Eibl MM: Long-term influence of adjuvant therapy on natural killer cell activity in breast cancer 278
- Trevenen CL → McGarry RC, et al. 47
- Tsao JY → Ichinose Y, et al. 7
- Uracz W, Stachura J, Pituch-Noworolska A, Popiela T, Czupryna A, Zembala M: The altered expression of MHC-class II determinants on monocytes of cancer patients 171
- Van Den Eynde B → Weynants P, et al. 228
- Vánky F, Stuber G, Willems J, Sjöwall K, Larsson B, Böök K, Ivert T, Péterffy A, Klein E: Importance of MHC antigen expression on solid tumors in the in vitro interaction with autologous blood lymphocytes 213
- Varesio L → Blasi E, et al. 109
- Vargas-Cortes M → Hansson Y, et al. 205
- Vore SJ → Germolec DR, et al. 121
- Voth R, Rossol S, Gallati H, Pracht I, Laubenstein HP, Hess G, Müller WEG, Schröder HC, Jochum C, Meyer zum Büschenfelde KH: In vivo and in vitro induction of natural killer cells by cloned human tumor necrosis factor 128
- Wauters P → Weynants P, et al. 228
- Weynants P, Wauters P, Coulie PG, Van Den Eynde B, Symann M, Boon T: Cytolytic response of human T cells against allogeneic small cell lung carcinoma treated with interferon gamma 228
- Willems J → Vánky F, et al. 213
- Wiltout RH → Blasi E, et al. 109
- Wise JA, Mokyr MB, Dray S: Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas 191
- Wisse E → Bouwens L, et al. 137
- Wolf H → Tichatschek E, et al. 278
- Wong JH, Aguero B, Gupta RK, Morton DL: Recovery of a cell surface fetal antigen from circulating immune complexes of melanoma patients 142
- Yachi A → Fukuda Y, et al. 26
- Yamamoto H → Katano M, et al. 198
- Zanetta G → Allavena P, et al. 69
- Zembala M → Uracz W, et al. 171
- Zielinski CC → Tichatschek E, et al. 278
- Zigheboim J → Nio Y, et al. 246
- Zimmermann JL → Johnson DA, et al. 241

Indexed in *Current Contents*

Subject index of volume 27

- Acyltriptide 33
- Adjuvant chemotherapy 278
- Agrimonin 59
- Antibody
 - ADCC 26
 - monoclonal 26, 154, 241, 267
 - targeting 17
- Antigen
 - DR 63
 - HLA 171
 - MHC 205, 213
 - tumor 142, 261
- Autotumor reactivity 213
- BCNU 38
- Biological response modifiers 33
- Bladder carcinoma 205
- Breast cancer 278
- Busulfan 89
- Chemotactic peptide (FMLP) 1
- Chlorinated hydrocarbons 77
- Colorectal carcinoma 137, 154, 233
- Cyclophosphamide 191
- Cytokines 97
- Cytotoxicity
 - antibody dependent 26
 - autologous reaction 147
 - cell mediated 59
 - cellular 177
 - MHC non-restricted 205
 - NK 128, 255
 - T cell 38, 183, 228
 - tumor 33
- Fatty acid maltose 272
- Gastric carcinoma 233
- Hepatocarcinogenesis 121
- Immune complexes 142
- Immune function 121
- Immunochemotherapy 163
- Immunocompetence 77
- Immunoconjugates
 - daunomycin 267
 - vinca 241
- Immunomodulation 191
- Immunotherapy 223
- Immunotoxins 95, 233
- Interferon
 - alpha 246
 - beta 163
 - gamma 33, 228, 261
- Interleukin-1 7
- Interleukin-2 53, 82, 255
 - human recombinant 13
- Kupffer cells 137
- LAK cells 13, 38, 53, 82, 97
- Leukemia 77, 89, 177, 183
- Liposomes 1
- Lung carcinoma
 - small cell 228
- Lymphocytes 69, 77, 213, 255
- Macrophage 1, 38, 109, 133
- Melanoma 142
- Metastasis 114, 154
- Methotrexate 17
- Mitogen 272
- Monoclonal antibody 26, 154, 241, 267
- Monocytes 7, 33, 171
- Monokines 7
- Mononuclear cells 82, 198
- Neuroblastoma 47, 82
- NK cells 38, 47, 59, 114, 128, 137, 163, 255, 278
- OK-432 97, 198, 246
- Oncogenes 109
- Ovarian carcinoma 63, 69, 246
- Polynucleotide
 - double stranded 114
- Prostaglandin E 133
- Radiotherapy 278
- Suppressor cells 147
- T cell
 - clones 205
 - helper 223
 - human 228
 - noncytolytic Lyt-2⁺ 261
- TGF-beta 53
- Thymocytes 13, 103
- TNF 7
- Tumor growth inhibitory factor 198
- Tumor necrosis factor 128, 246
- Vaccinia virus 223
- Vinca alkaloids 241

